The U.S. Food and Drug Administration (FDA) has cleared the first blood test to aid in diagnosis of Alzheimer's disease. The test detects amyloid plaques, a hallmark of Alzheimer's disease, through a ...

In the assessment of 12-month price targets, analysts unveil insights for Insmed, presenting an average target of $99.0, a ...

INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

In a classic example of scientific problem solving, scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI) and colleagues have published a paper introducing a promising new ...

infection rate of NTM in adults with non-CF bronchiectasis with the classification of NTM. For missing information, we communicated with the authors; if the information was unavailable after ...

abscessus infections are subject to drug-to-drug ... nontuberculous mycobacteria (NTM), as well as against Mycobacterium avium complex (MAC), and TB. M. abscessus remains the primary target.

Insmed (INSM) is at a critical point. While its revenue stream is from ARIKAYCE for Mycobacterium Avium Complex lung disease, the company's future and potential share price appreciation are ...

Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the ...

Accurate detection is essential to prevent misdiagnosis and ensure the right treatment, particularly in cases involving drug-resistant TB or NTM infections. The Hi-PCR ® MTB/NTM Probe PCR Kit ...

Even though microbial keratitis is a preventable cause of blindness, it's a complex infection to treat, and many patients have lasting vision impairment. Maria A. Woodward, M.D., an associate ...